Robbins LLP Signals Class Action Against PepGen Inc. Over Investor Alerts

Robbins LLP Alerts Investors on PepGen Class Action

Overview of the Class Action

On June 12, 2025, Robbins LLP reminded stockholders of a class action lawsuit filed on behalf of those who purchased or acquired securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024, and March 3, 2025. The biotechnology company is recognized for its focus on developing oligonucleotide therapeutics specifically aimed at tackling severe neuromuscular and neurologic diseases. Their lead product candidate, PGN-EDO51, is intended for treating Duchenne muscular dystrophy (DMD).

Allegations Against PepGen

The lawsuit alleges that PepGen misled its investors about the viability and safety of its drug candidate. Key points from the complaint indicate that:

1. PepGen did not disclose critical information about PGN-EDO51’s safety and effectiveness, leading to inflated perceptions of its potential.
2. The CONNECT2 study was allegedly deemed unsafe or inadequate for FDA approval, contradicting the company's assertions.
3. Due to these issues, the likelihood of halting the CONNECT2 study was understated, significantly overstating the prospects of PGN-EDO51 in its clinical and commercial phases.
4. Public statements made by PepGen regarding these matters have been considered materially false and misleading.

Impact of Public Disclosures

On January 29, 2025, PepGen reported safety concerns associated with the CONNECT1 study in a press release, which highlighted that dosing for one participant was paused due to a concerning reduction in their estimated glomerular filtration rate. Additionally, Health Canada requested further information to allay safety concerns before allowing more participants into the study. Following this announcement, PepGen’s stock price fell by $0.40 per share, translating to a drop of 21.74% by the next day.

Later, on March 4, 2025, PepGen declared a voluntary pause of the CONNECT2 study until they could analyze results from the CONNECT1 study at the 10 mg/kg dosing level. This resulted in even further declines, with another drop of $0.53 per share, roughly 18.86%, closing at $2.28 per share on the same day.

How to Participate

Shareholders who wish to act as lead plaintiffs in this class action must file a motion by August 8, 2025. While participation is not a requirement for recovery, potential plaintiffs need to actively apply if they want to direct the litigation.

Robbins LLP operates on a contingency fee basis, which means that shareholders will incur no expenses unless they recover losses. The firm, dedicated to shareholder rights since its establishment in 2002, emphasizes holding company executives accountable and improving governance structures.

Stay informed by registering for alerts regarding class action settlements involving PepGen or other companies engaging in misconduct.

Conclusion

The ongoing situation surrounding PepGen Inc. underlines the critical role of transparency in the biotechnology industry, especially concerning investor trust. Robbins LLP continues its mission to support investors who are affected by potential misrepresentation and harm pertaining to their investments.

For further assistance or to learn about participation in the class action, potential claimants can visit Robbins LLP’s website or reach out directly to attorney Aaron Dumas, Jr., or contact the firm at (800) 350-6003.